Incyte (INCY) Stock Forecast & Price Target

$68.84 +1.78 (+2.65%)

(As of 12/20/2024 05:31 PM ET)

Incyte - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 20 Analyst Ratings

Sell
1

Hold
11

Buy
8

Based on 20 Wall Street analysts who have issued ratings for Incyte in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 1 has given a sell rating, 11 have given a hold rating, and 8 have given a buy rating for INCY.

Consensus Price Target

$76.29
10.83% Upside

According to the 20 analysts' twelve-month price targets for Incyte, the average price target is $76.29. The highest price target for INCY is $97.00, while the lowest price target for INCY is $52.00. The average price target represents a forecasted upside of 10.83% from the current price of $68.84.

Get the Latest News and Ratings for INCY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Incyte and its competitors.

INCY Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)	10 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$76.29	$77.16	$73.24	$80.79
Forecasted Upside	10.83% Upside	7.58% Upside	14.22% Upside	28.54% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

INCY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

INCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Incyte Stock vs. The Competition

Type	Incyte	Medical Companies	S&P 500
Consensus Rating Score	2.35	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	10.83% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent INCY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/19/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$68.00 ➝ $70.00	+3.12%
12/17/2024	UBS Group 4 of 5 stars	C. Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$77.00	+11.30%
12/13/2024	William Blair 2 of 5 stars		Reiterated Rating	Outperform
11/19/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral
11/14/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$72.00 ➝ $80.00	+1.19%
10/30/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$92.00 ➝ $97.00	+32.17%
Get the Latest News and Ratings for INCY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.
10/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$63.00 ➝ $70.00	-4.18%
10/30/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$64.00 ➝ $69.00	-5.35%
10/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$65.00 ➝ $71.00	-2.74%
10/30/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$81.00 ➝ $82.00	+12.33%
10/30/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform	$48.00 ➝ $52.00	-28.76%
10/29/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$68.00 ➝ $90.00	+22.88%
10/1/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$84.00	+27.08%
9/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Devarakonda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$83.00 ➝ $74.00	+11.40%
9/17/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform
9/16/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$86.00 ➝ $92.00	+40.59%
8/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$55.00 ➝ $60.00	-6.93%
5/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$88.00 ➝ $80.00	+53.32%
2/23/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$81.00	+32.98%
2/14/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$67.00 ➝ $68.00	+14.59%
12/14/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$82.00 ➝ $77.00	+20.29%
12/13/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$78.00	+26.09%
5/3/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
3/24/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform	$61.00	-12.39%
2/16/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$95.00 ➝ $100.00	+26.58%
2/8/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight	$100.00	+25.14%
2/8/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$95.00 ➝ $100.00	+23.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:49 PM ET.

INCY Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Incyte is $76.29, with a high forecast of $97.00 and a low forecast of $52.00.
: 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There is currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
: According to analysts, Incyte's stock has a predicted upside of 10.83% based on their 12-month stock forecasts.
: Over the previous 90 days, Incyte's stock had 1 upgrade by analysts.
: Incyte has been rated by research analysts at Bank of America, BMO Capital Markets, Cantor Fitzgerald, Citigroup, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Royal Bank of Canada, The Goldman Sachs Group, UBS Group, Wells Fargo & Company, William Blair, and Wolfe Research in the past 90 days.
: Analysts like Incyte less than other "medical" companies. The consensus rating for Incyte is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INCY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

Click here to see the details because I believe a lot of people will get rich.

This page (NASDAQ:INCY) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Stock Forecast & Price Target